Immunicum: Collaboration And Supply Agreement Signed
Edison | Nov 19, 2018 07:42AM ET
Immunicum AB (ST:IMMUN) has announced that it has signed a collaboration and supply agreement with Pfizer (NYSE:PFE) and Merck KGaA, Darmstadt, Germany for the checkpoint inhibitor (CPI) Bavencio to be used in combination with ilixadencel in the Phase Ib/II ILIAD study. Bavencio (avelumab) is marketed by Pfizer and Merck KGaA, and approved in the US and EU. The availability of Bavencio at no cost to Immunicum in the ILIAD study potentially opens up European study sites, which will be aided by the recent share issues.
Icing on the cake
Building on a very busy summer, which included stock issues and agreement on the ILIAD study protocol with the FDA, Immunicum has now announced a collaboration and supply agreement with Pfizer and Merck KGaA for the CPI Bavencio (avelumab) to be used in combination with ilixadencel. We had already removed the cost of CPI supply from our model, but the endorsement by Pfizer and Merck KGaA makes expansion of the ILIAD study to European centres (where CPIs are not readily available) possible, and thus recruitment of the Phase II portion could be faster than we had estimated. Bavencio was approved by the FDA in March 2017 for metastatic Merkel cell carcinoma (MCC), and for urothelial carcinoma in May 2017. Bavencio was approved for metastatic MCC in the EU in September 2017. Before Immunicum’s announcement, the PD-L1 monoclonal antibody was in 18 combination studies in 2017, four of which were immunoncology (I/O) combination studies.
To read the entire report Please click on the pdf File Below..
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.